Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Preferred Shares (2023 - 2025)

SAB Biotherapeutics' Preferred Shares history spans 3 years, with the latest figure at $3.0 for Q4 2025.

  • For Q4 2025, Preferred Shares fell 40.0% year-over-year to $3.0; the TTM value through Dec 2025 reached $3.0, down 40.0%, while the annual FY2025 figure was $3.0, 40.0% down from the prior year.
  • Preferred Shares reached $3.0 in Q4 2025 per SABSW's latest filing, down from $64.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $64.0 in Q3 2025 to a low of $3.0 in Q4 2025.
  • Average Preferred Shares over 3 years is $11.33, with a median of $5.0 recorded in 2023.
  • The largest YoY upside for Preferred Shares was 1180.0% in 2025 against a maximum downside of 40.0% in 2025.
  • A 3-year view of Preferred Shares shows it stood at $5.0 in 2023, then changed by 0.0% to $5.0 in 2024, then tumbled by 40.0% to $3.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Preferred Shares are $3.0 (Q4 2025), $64.0 (Q3 2025), and $5.0 (Q2 2025).